101 results about "Ischaemia-reperfusion injury" patented technology

Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and / or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R<1 >, R<2> and and R<3> are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

The invention relates to application of CREG protein, in particular to application of the CREG protein or an active fragment of the CREG protein to preparation of drugs for preventing and / or treating myocardial Ischemia-reperfusion injury. The invention further relates to application of a recombinant vector or recombinant cell expressing the CREG protein or an active fragment of the CREG protein to preparation of the drugs for preventing and / or treating the myocardial Ischemia-reperfusion injury. The invention further relates to a preparation compound which contains the CREG protein or an active fragment of the CREG protein as well as the recombinant vector or recombinant cell expressing the CREG protein or the active fragment of the CREG protein, and can inhibit down-regulated expression of the CREG protein or an active fragment of the CREG protein or promote up-regulated expression of the CREG protein or an active fragment of the CREG protein.

The invention relates to a phenylpropanoid glycosides composition extracted from traditional tibetan medicine incarvillea younghusnandii and a preparation method, comprising an incarvillea younghusnandii phenylpropanoid glycosides compound A and an incarvillea younghusnandii phenylpropanoid glycosides compound B, wherein, the weight ratio of the compound A and the compound B is 60 to 90 : 40 to 10; and the total content of two compounds is 70% to 100% of the total weight of the phenylpropanoid glycosides. The phenylpropanoid glycosides composition is characterized in that: when the composition is used as an anti-oxygenic medicine or health care product, the composition can be used for treating the disease caused by damaging the related free radicals such as aging, atherosclerosis and ischemia-reperfusion injury; and when the composition is used as the antioxidant additive for the food and the forage, the composition can be used for protecting or alleviating the forage from rancidity and metamorphosis, the nutritive value from decreasing and the palatability from variation. The phenylpropanoid glycosides composition has the advantages that: the preparation prepared with the composition as main component can be tablet, capsule, granule, injection, dropping pill, liquid preparation and powder; and the new plant natural antioxidant with nature, efficiency and low toxicity is provided.

The invention belongs to the technical field of medicines, and particularly relates to a JNK (stress-activated kinases,SAPK) inhibitor compound as shown in the general formula (I), pharmaceutically acceptable salts or stereoisomers thereof, preparation method of the compounds, pharmaceutical preparations containing the compounds, and use of the compounds in preparing medicines for treatment and / or prevention of ischemia reperfusion injury, diabetes, neurodegenerative diseases, chronic inflammation, pulmonary fibrosis, liver fibrosis, fatty liver and liver cirrhosis, wherein R1, R2, R3, R4 and R5 are as defined in the specification.

The invention relates to the field of medical technology, which discloses a new usage of a petasites tricholobus franch extract and the contained bakkenolide compound in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases. The biological activity tests show that, the petasites tricholobus franch extract and the contained bakkenolide compound can significantly reduce the encephalic necrosis percentage of the rats with local cerebral ischemia, improve the behavior score of the ischemic rats and alleviate volume of brain edema and cerebral infarction of the rats with ischemia reperfusion injury, thus prompting that the petasites tricholobus franch extract and the contained bakkenolide compound have significant protective effect on the cerebral ischemia injury. The petasites tricholobus franch extract and the contained bakkenolide compound can further significantly reduce the J-point displacement caused by ISO and the LDH level in plasma, significantly reduce the scope of myocardial ischemic myocardial infarction of the rats caused by coronary artery ligation and lower the LDH level in the plasma of the rats with the myocardial ischemia. As the petasites tricholobus franch extract and the contained bakkenolide compound have good effects on the prevention and the treatment for heart and brain ischemic diseases aspects, the petasitestricholobus franch extract and the contained bakkenolide compound can be used in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases, including coronary heart disease, cerebral ischemia, cerebral infarction (stroke), myocardial infarction and so on.

Methods of prolonging survival of a transplanted organ, as well as methods of preventing or attenuating rejection of a transplanted organ are provided. These methods involve contacting the organ with an inhibitor of complement activity (e.g., a complement inhibitor that has a maximum molecular weight of 70 kDa and / or a half-life shorter than 10 days, such as a CR2-FH fusion protein or a single chain anti-C5 antibody), prior to transplantation The methods also include administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. A pretreatment with an alternative complement inhibitor was found to be effective in improving graft survival and decreasing ischemia-reperfusion injury in animal.

The invention discloses an application of 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside in the preparation of microcirculatory disturbance improvement medicines. The microcirculatory disturbance improvement medicines comprise 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside as an effective active component, and one or more pharmaceutically acceptable auxiliary agents, especially gastrodin and / or water-soluble cyclodextrin derivatives and PEG400 and mannitol, wherein the structural formula of 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside is shown in the specification. The microcirculatory disturbance improvement medicines treat 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside as the effective active component, and are used for improving disturbances caused by cerebral microvascular damages and / or disturbances caused by ischemia reperfusion damages and / or disturbances caused by leukocyte adhesion damages, and / or disturbances caused by peroxides. Normal mice of Kunming species and artificially induced microcirculatory disturbance model mice undergo tail vein injection treatment, and results of the observation of arteriole and venule systole and capillary network under a microcirculatory microscope show that 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside has an obvious expansion effect on the blood vessels of the normal mice, can obviously resist the reduction of the arteriole and venule systole and capillary network opening number of the microcirculatory disturbance model mice and can obviously resist the reduction of the blood flow speed.

The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and / or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.

The invention discloses an application of GSDMD as an early diagnosis marker of myocardial ischemia-reperfusion injury, and particularly discloses a diagnostic reagent or a kit for detecting myocardial ischemia-reperfusion injury prepared from GSDMD. The GSDMD is remarkably increased after myocardial ischemia reperfusion is verified at animal and human levels, so that the myocardial ischemia reperfusion injury can be diagnosed and predicted by detecting the level of the GSDMD in peripheral blood or in-vitro myocardial tissue samples of a tested individual, and a new way is provided for early diagnosis of the myocardial ischemia reperfusion injury.

Dibenzo quinolizine compound entity has relatively low hygroscopicity and relatively high storage stability, and is applicable to preparation of analgesic, sedative, hypnotic and tranquillizing medicines, medicines for treating hypertension, arrhythmia and functional dyspepsia, stopping cough, resisting schizophrenia and heroin and other drug dependence, reversing tumor cell drug resistance and delaying or reducing myocardial ischemia reperfusion injury, calcium antagonists, and medicines for protecting the liver and preventing visceral implicated reaction and other effects, which are applied to humans or animals.

The invention relates to a nano-drug for preventing or treating cerebral ischemia-reperfusion injury as well as a preparation method and application of the nano-drug. Cerebral ischemia is a cerebrovascular disease which has the greatest threat to human beings, and oxidative injury, inflammatory response and subsequent excitotoxic cell death can be caused by reperfusion as soon as possible. According to the nano-drug, dopamine is oxidized under an alkaline condition to form dopamine quinone, the dopamine quinone is further oxidized to form polydopamine nanoparticles with supramolecular structures, the formed particles are smooth and round in surface, good in sphericity degree and uniform in particle size distribution, a good dispersion state is kept in a solution, and through in-vitro and in-vivo experiments, the polydopamine nanoparticles prove the biological safety. Application of the polydopamine nanoparticles to a cerebral ischemia model shows that the polydopamine nanoparticles canrelieve cerebral ischemia-reperfusion injury, inhibit inflammatory reaction, inhibit activation of an NF-kappa B signal channel and inhibit excessive activation of microglial cells, and have the potential of inhibiting cerebral inflammatory reaction and relieving cerebral ischemia-reperfusion injury.

The invention provides application of trehalose in preparation of a medicine for relieving renal ischemia-reperfusion injury, and belongs to the field of biological medicines. The application proves that trehalose can alleviate ischemia-reperfusion induced acute kidney injury related diseases, including acute kidney injury renal function, oxidative stress, renal tubular cell apoptosis, renal inflammatory cell infiltration and the like, by enhancing autophagy, thereby providing a theoretical basis for widening the possible application range of trehalose. As trehalose has been approved to be a safe food component by American Food and Drug Administration at present and has been applied to food preservation and other work, it is found that effective clinical drugs are extremely likely to be provided for prevention and treatment of AKI.

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

The invention discloses a method for constructing a blood-spinal cord barrier (BSCB) oxygen-glucose deprivation / reoxygenation (OGD / R) injury model and an application thereof. Spinal cord derived microvascular endothelial cells were cultured in the upper chamber and mixed glial cells were cultured in the bottom chamber of the transwell culture system to construct the in vitro BSCB model. Microvascular endothelial cells in the upper chamber of transwell and mixed glial cells in the lower chamber of transwell interact with each other by secreting cytokines to form molecular membranes with good barrier function. OGD / R can effectively simulate the injury of BSCB induced by ischemia / reperfusion in vivo, and can more directly and accurately understand the changes of structure and function of BSCBafter ischemia / reperfusion injury. The results of the study have a high reference value, thus providing an effective basis for clinical study of BSCB.

The invention discloses a medical application of PF429242 in protection of ischemia reperfusion injury. Specifically, the invention provides an application of PF429242, an enantiomer thereof, a racemate thereof or pharmaceutically acceptable salt thereof in screening and preparing medicines for preventing and / or treating cerebral ischemia-reperfusion injury. A large number of experiments prove that the PF429242, the enantiomer, the racemate or the pharmaceutically acceptable salt of the PF429242 can effectively reduce brain cell injury and dysfunction caused by cerebral ischemia-reperfusion ofrats, and has an obvious protective effect on neurobrain cells.

The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.

The invention discloses a salicylamide derivative crystal and specifically discloses a compound shown in the formula 1. Under Cu-K alpha radiation, in the powder x-ray diffraction pattern represented by 2 theta angle, the compound has a diffraction peak at about 9.4 degrees. The invention also discloses a preparation method of the compound shown in the formula 1, a pharmaceutical composition containing the compound, and a use of the compound or its pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers in preparation of drugs for treating or preventing cancers, inflammation, autoimmune disease, diabetes, diabetic complication, infection, cardiovascular diseases and ischemia-reperfusion injuries. The compound shown in the formula 1 has good drug properties.

Compositions comprising inositolphosphoglycans (IPGs) and ribose are disclosed, and their use in the prevention or treatment of ischaemic-reperfusion injury. This treatment increases the energy generating systems of cells by employing the mitochondrial oxidative restoration system. The use of the compositions in preserving organs for transplantation is also disclosed.

The invention discloses an application of icariin in preparation of a medicine for promoting angiogenesis. The icariin is used for preparing the medicine for promoting angiogenesis. Animal experimental verification proves that the prepared medicine composition can be used for preventing and treating ischemic injuries including perpetual ischemic injuries and ischemia-reperfusion injuries of limbs and intestinal tracts (small intestines and large intestines). The icariin has the advantages of being wide in source of raw materials, easy to obtain, simple and practical in preparation of the medicine and having a good curative effect.

The invention provides application of FG4592 in preparation of a medicine for preventing and treating chronic kidney diseases caused by ischemia-reperfusion injury. The application is characterized in that a new candidate compound is provided for the chronic kidney diseases caused by the ischemia-reperfusion injury; the FG4592 is an HIF prolyl hydroxylase activity inhibitor. In addition, the FG4592 can be prepared into a composition of the medicine for the chronic kidney diseases. Specifically, the FG4592 can promote neogenesis of kidney blood vessels, relieve the kidney oxidative stress caused by the ischemia-reperfusion injury and reduce the kidney fibrosis level. The application range of the FG4592 is expanded; the FG4592 is used as the candidate compound for preventing and treating the chronic kidney diseases caused by the ischemia-reperfusion injury to be developed and applied.

The invention provides a multifunctional liposome based on ROS sensitivity and H2S response as well as a preparation method and application of the multifunctional liposome. The multifunctional liposome comprises a PFC carrier, phospholipid and cholesterol, wherein ROS reaction groups and H2S donors are introduced into the PFC carrier through chemical bonds; meanwhile, the invention also entraps hydroxysafflor yellow A; the mass ratio of the phospholipid to the hydroxysafflor yellow A is (2-4): 1; the molar ratio of the phospholipid to the PFC carrier is (4-8): 1. The ROS reactive group and the H2S donor are introduced into the PFC carrier, and the liposome prepared by using the PFC carrier has ROS sensitivity and H2S response functions. The liposome simultaneously entraps a strong water-soluble drug hydroxysafflor yellow A, so that the slow release time of HSYA is prolonged, the cell penetrating ability of HSYA is improved, and the renal ischemia reperfusion injury is treated in multiple aspects.

The invention provides a pharmaceutical composition and application thereof. Specifically, the pharmaceutical composition comprises salvianolic acid B as a first active ingredient and ginsenoside Rg1as a second active ingredient, wherein the weight ratio of the first active ingredient to the second active ingredient is 5: (1-4.5). The pharmaceutical composition has a better active ingredient ratio than the prior art, has a more excellent curative effect in the aspects of preventing and / or treating ischemic diseases and ischemia-reperfusion tissue and organ injuries, and can be used for treating ischemia and / or ischemia-reperfusion injuries of different tissues and organs.

The invention relates to the technical field of dental pulp stem and fine treatment, in particular to a method for treating cerebral ischemia reperfusion injury by using a dental pulp stem cell exosome. The method comprises the steps: extraction of exosomes from dental pulp stem cells, extraction of third molars without dental caries and periodontal lesions from healthy volunteers at age of 18 to 30 years-disinfection of tooth surface with 75% alcohol-removal of dental pulp from dental drill-cutting into pieces of 1 mm3-flushing three times with PBS containing 2.5% antibiotic-placement of pulp tissue in 1.5 ml EP tube with digestion of 3 mg / ml type I collagenase-placement in dispase of 4 mg / mL for 30 minutes at 37 DEG C-cell resuspension- and culturing in a 5% CO2 incubator at 37 DEG C; brain tissue is an organ most sensitive to ischemia and hypoxia of the body, irreversible brain injury occurs after blood flow supply is interrupted for several minutes, animal experiments find that the exosome from the dental pulp stem cells can reduce the cerebral infarction area after cerebral ischemia-reperfusion injury of a mouse, and a key technology is provided for clinical application of the dental pulp stem cell exosome in treatment of cerebral ischemia-reperfusion injury.

The invention discloses an application of glucogalactooligosaccharide in preparation of a medicine for treating and / or preventing ischemia-reperfusion injury. The glucogalactooligosaccharide disclosed by the invention can be used for remarkably relieving postoperative liver injury, kidney injury, brain injury and the like of ischemia reperfusion mice, is safe and non-toxic, has a strong drug effect, and has a very good medicinal prospect in prevention and treatment of ischemia reperfusion injury.